Abstract Human papillomavirus (HPV)-positive (HPV+) oropharyngeal squamous cell
carcinoma (OPSCC) has one of the most rapidly increasing incidences of any cancer in high …

Head and neck cancer is the seventh most common type of cancer worldwide and comprise
of a diverse group of tumours affecting the upper aerodigestive tract. Although many different …

Background First-line chemotherapy for advanced esophageal squamous-cell carcinoma
results in poor outcomes. The monoclonal antibody nivolumab has shown an overall …

The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …

Therapeutic cancer vaccines have undergone a resurgence in the past decade. A better
understanding of the breadth of tumour-associated antigens, the native immune response …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Immune-checkpoint inhibitors targeting PD-1 or PD-L1 have already substantially improved
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …

Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has greatly improved
the clinical efficacy of malignant tumor therapy. ICI-mediated antitumor responses depend …

PURPOSE Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in
recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048. Post hoc …

Most head and neck cancers are derived from the mucosal epithelium in the oral cavity,
pharynx and larynx and are known collectively as head and neck squamous cell carcinoma …